Protein arginine methyltransferase 1 (PRMT1) serves as a crucial regulator of post-translational modifications of proteins. While PRMT1 has been implicated in the progression of various cancers, its specific role in chronic lymphocytic leukemia (CLL) remains to be fully elucidated. This study aimed to investigate the oncogenic function of PRMT1 and assess the therapeutic efficacy of a selective PRMT1 inhibitor, C7280948, in CLL. Elevated expression of PRMT1 was observed in CLL cells and was asso...